These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 34835288)
61. Would New SARS-CoV-2 Variants Change the War against COVID-19? Redwan EM; Elrashdy F; Aljabali AAA; Baetas-da-Cruz W; Barh D; Brufsky AM; Hassan SS; Lundstrom K; Serrano-Aroca Á; Takayama K; Tambuwala MM; Uhal BD; Uversky VN Epidemiologia (Basel); 2022 Apr; 3(2):229-237. PubMed ID: 36417254 [TBL] [Abstract][Full Text] [Related]
62. The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters. Golec M; Konka A; Fronczek M; Zembala-John J; Chrapiec M; Wystyrk K; Kasperczyk S; Brzoza Z; Bułdak RJ Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298503 [TBL] [Abstract][Full Text] [Related]
63. Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old. Tomaiuolo R; Di Resta C; Viganò M; Banfi G; Russo C; Linardos G; Ranno S; Perno CF; Giuffrida F Sci Rep; 2022 Jul; 12(1):12446. PubMed ID: 35858893 [TBL] [Abstract][Full Text] [Related]
64. Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Criscuolo E; Giuliani B; Ferrari D; Ferrarese R; Diotti RA; Clementi M; Mancini N; Clementi N Viruses; 2022 Jun; 14(6):. PubMed ID: 35746703 [TBL] [Abstract][Full Text] [Related]
65. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. Sakamoto A; Yoshimura M; Itoh R; Ozuru R; Ishii K; Sechi Y; Nabeshima S; Hiromatsu K Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746438 [TBL] [Abstract][Full Text] [Related]
66. Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course. Swadźba J; Anyszek T; Panek A; Chojęta A; Wyrzykowska K; Martin E Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741236 [TBL] [Abstract][Full Text] [Related]
67. Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity. Morgiel E; Szmyrka M; Madej M; Sebastian A; Sokolik R; Andrasiak I; Chodyra M; Walas-Antoszek M; Korman L; Świerkot J Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632467 [TBL] [Abstract][Full Text] [Related]
68. SARS-CoV-2-specific CD4 Wang Z; Yang X; Mei X; Zhou Y; Tang Z; Li G; Zhong J; Yu M; Huang M; Su X; Lin B; Cao P; Yang J; Ran P Signal Transduct Target Ther; 2022 Apr; 7(1):132. PubMed ID: 35461307 [TBL] [Abstract][Full Text] [Related]
69. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia. Yang SL; Mat Ripen A; Leong CT; Lee JV; Yen CH; Chand AK; Koh K; Abdul Rahim NAB; Gokilavanan V; Mohamed NNEB; Sevalingam RKA; Sulaiman N; Ab Razak AKB; Mohd Nor NHB; Pong MK; Tai KY; Toh V; Woon YL; Peariasamy KM Emerg Microbes Infect; 2022 Dec; 11(1):1262-1271. PubMed ID: 35412409 [TBL] [Abstract][Full Text] [Related]
70. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Bakasis AD; Bitzogli K; Mouziouras D; Pouliakis A; Roumpoutsou M; Goules AV; Androutsakos T Viruses; 2022 Jan; 14(2):. PubMed ID: 35215801 [TBL] [Abstract][Full Text] [Related]
71. Performance evaluation of an automatic chemiluminescence immune platform for SARS-CoV-2 neutralizing antibody after vaccination in real world. Li M; Jiang R; Wang E; Xiong D; Ou T; Zhang X; Dou X BMC Infect Dis; 2022 Feb; 22(1):157. PubMed ID: 35168557 [TBL] [Abstract][Full Text] [Related]
72. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271 [TBL] [Abstract][Full Text] [Related]
73. Antibody titres decline 3-month post-vaccination with BNT162b2. Favresse J; Bayart JL; Mullier F; Elsen M; Eucher C; Van Eeckhoudt S; Roy T; Wieers G; Laurent C; Dogné JM; Closset M; Douxfils J Emerg Microbes Infect; 2021 Dec; 10(1):1495-1498. PubMed ID: 34232116 [TBL] [Abstract][Full Text] [Related]
74. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine. Ferrari D; Clementi N; Criscuolo E; Ambrosi A; Corea F; Di Resta C; Tomaiuolo R; Mancini N; Locatelli M; Plebani M; Banfi G Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835288 [TBL] [Abstract][Full Text] [Related]
75. Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine. Ferrari D; Ambrosi A; Di Resta C; Tomaiuolo R; Locatelli M; Banfi G J Immunol Methods; 2022 Jul; 506():113293. PubMed ID: 35660546 [TBL] [Abstract][Full Text] [Related]
76. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]